Table 3.

CFA, CNA and stool characteristics at baseline and end of double-blind period, unadjusted mean ± s.d. (full analysis sample)

	Pancreatin		Placebo
	Baseline (n = 32)	End of double-blind phase (n = 31)*	Baseline (n = 26)	End of double-blind phase (n = 25)*
CFA, %
Full analysis sample	56.9 ± 17.6	76.6 ± 17.2	49.5 ± 23.5	46.3 ± 31.1
Subjects with positive CFA values	56.9 ± 17.6	76.6 ± 17.2	55.4 ± 19.1§	55.5 ± 18.3¶
By malignancy status
Malignancy†	54.8 ± 18.9	69.4 ± 23.7	62.7 ± 12.4	46.3 ± 32.4
No malignancy (chronic pancreatitis) ‡	57.8 ± 17.5	79.5 ± 13.3	46.4 ± 24.6	46.3 ± 31.7
CNA, %	55.3 ± 22.2	73.0 ± 16.6	49.6 ± 26.9	39.7 ± 39.0
Stool fat, g/day	44.5 ± 22.4	21.6 ± 12.4	49.3 ± 30.1	55.8 ± 37.3
Stool nitrogen, g/day	6.7 ± 3.5	3.8 ± 2.1	6.7 ± 3.6	8.4 ± 5.3
Fat intake, g/day	104.3 ± 31.5	98.9 ± 31.3**	97.4 ± 33.4	102.5 ± 25.7††
Nitrogen intake, g/day	15.7 ± 7.0	15.0 ± 5.9**	13.6 ± 3.3	14.3 ± 3.2††
Stool weight, g/day	451 ± 210	282 ± 145	487 ± 257	514 ± 268
Number of stools per day	2.5 ± 1.5	1.6 ± 1.2**	2.3 ± 1.7	2.8 ± 1.5

CFA, coefficient of fat absorption; CNA, coefficient of nitrogen absorption; s.d., standard deviation.

^*There were no stool analysis data at the end of the double-blind period for one subject in the pancreatin group and one subject in the placebo group.

^†Number of patients was nine in pancreatin group and five in the placebo group.

^‡Number of patients was 23 in the pancreatin group and 21 in the placebo group.

^§n = 22;

^¶n = 21;

^**n = 32;

^††n = 26;